Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present ten abstracts from our portfolio and advancing pipeline at the European Society for Medical Oncology (ESMO) ...

MIBC requires a multimodal treatment approach, with radical cystectomy as the gold standard and bladder-sparing options for select patients. Adjuvant immunotherapies, such as nivolumab and ...

The ESMO 2025 Congress will highlight late-breaking abstracts on RCC and bladder cancer, focusing on immune checkpoint ...

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

Dr Mark Kris continues his discussion on neoadjuvant vs adjuvant therapy for locally advanced lung cancer, offering his take ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...